US stocks surged across the board, and Chinese assets also rallied sharply—how should we interpret this trend? What does it reflect beneath the surface?

This outcome has effectively eliminated that discount all at once. The Democrats not only secured 258 seats in the House of Representatives but also won over 54 seats in the Senate—even flipping a U.S. Senate seat in deeply red Texas for the first time in over thirty years. More crucially, the 'Golden-haired' candidate did not dispute the results; instead, he explicitly accepted the outcome and signaled willingness to cooperate. The clarity of the election result, coupled with the peaceful signal of power transition, collectively removed the tail-risk scenario of 'political system failure' from market pricing models. The Dow Jones Industrial Average surged 1,569 points—or 3.03%—in a single day, while the S&P 500 rose 1.58%, essentially reflecting a relief-driven rebound driven by an immediate compression of risk premium. As Berenberg’s strategist put it: 'We’re seeing a strong relief rally as uncertainty dissipates'—a statement that couldn’t be more straightforward. Yet 'uncertainty removal' alone cannot fully explain the rally’s sustainability. A deeper driver is the return of policy visibility to markets under a divided government. Wall Street’s preference for a 'divided government' has never been about liking political gridlock per se, but rather because gridlock makes extreme policies harder to enact and existing rules harder to abruptly rewrite. A divided Congress simultaneously blocks major tax hikes and major spending bills, effectively locking corporate tax rates—historically low—into a predictable range. The same logic applies to bond markets: strengthened hard constraints on budget approvals and the debt ceiling systematically lower the probability of surprise fiscal deficits, thereby reinforcing the downward logic for long-end yields. In other words, what the market is buying isn’t 'what the Democrats will do,' but rather 'whatever either party attempts, it won’t go too far.' This institutional lock-in of policy pathways is far closer to the concept of 'predictability' embedded in Wall Street’s pricing models than any radical policy shift under single-party rule. That’s why short-term volatility forecasts across various election scenarios—Democratic sweep, divided Congress, or Republican retention of both chambers—were all remarkably narrow before the vote: implied S&P 500 short-term volatility remained within 1.25% across all cases. The result itself isn’t directional—the actual implementation of that result is. As for the simultaneous rally in Chinese assets—the Nasdaq Golden Dragon China Index jumped 3.49% in a single day, with leading U.S.-listed Chinese firms like Alibaba, Baidu, and Pinduoduo all rising sharply—the logic isn’t that the U.S. midterm elections directly improve China’s fundamentals. Rather, it reflects beta spillover from a broad-based global improvement in risk sentiment.

The U.S. proposes restrictions on investment in Chinese biotechnology companies.

The U.S. side has once again added biotechnology to its list of sectors subject to investment restrictions targeting China—this time led by the Treasury Department, which issued the proposal on Thursday. Frankly, the timing is intriguing: while major U.S. pharmaceutical companies queue up to acquire R&D pipelines in China, the U.S. government is trying to tighten the financial faucet. Here’s how things stand: the Treasury Department has added biotechnology to its list of sensitive technologies—alongside AI, semiconductors, and quantum computing—subject to restrictions on U.S. investment in foreign adversaries. Certain investments by U.S. investors into Chinese companies engaged in sensitive technologies now require mandatory reporting; others are outright prohibited. Notably, brain–computer interface (BCI) technology has also been included—targeting domestic startups aiming to compete with Neuralink. Keep in mind: this is still only a proposal, currently open for public comment; final rules won’t take effect until formally adopted—so there’s no immediate, tangible impact. What concerns me more is the emerging fissure: Big Pharma has become increasingly addicted to licensing deals with China in recent years—if their internal pipelines run dry, they must buy externally. Restricting investment and restricting collaboration are two distinct things, and the proposal itself admits the impact on pharma partnerships remains 'unclear.' Yet markets often price in worst-case assumptions first: Hong Kong–listed biotech firms—especially those reliant on U.S. dollar-denominated funds and whose valuations hinge on business-development (BD) expectations—may face an initial emotional hit. I believe part of this risk has already been priced in, given repeated warnings about expanding the restricted-technology list; however, the explicit inclusion of BCI represents a new variable—not yet fully reflected in prices. Conversely, purely domestically funded biotechs whose BD partners are major Western pharma companies (rather than U.S. dollar funds) would logically face less direct pressure—a direction worth monitoring. A quick aside: While the stated policy objective is 'national security,' the real parties footing the bill are American patients’ medicine cabinets—and these two goals have been at odds for years. Question to readers: If these final rules ultimately take effect, which group do you think will feel the pain first—the batch of Hong Kong–listed biotechs under Chapter 18A, or early-stage platform companies dependent on U.S. dollar funds for survival? This is not investment advice. — [Original] Headline: US Proposes Curbs on Investment in Chinese Biotech Firms The Trump administration is seeking to restrict American investment in Chinese biotechnology companies, potentially complicating financial ties at a time when US drugmakers are increasingly turning to China for new medicines. The US Treasury Department on Thursday added biotechnology to a list of sensitive technologies subject to restrictions on American investment in foreign adversaries, citing national security concerns.

China's Cleantech Stocks Jump as Investors Bet on US Policy Shift

17 hours ago

China's cleantech stocks surged following election results suggesting Democratic support for clean energy, boosting major suppliers like Sungrow and CATL despite existing tariffs. Analysts note gains are sentiment-driven, though potential policy shifts could benefit Chinese exporters in solar and battery sectors.

reuters

2026-11-04

China's Cleantech Stocks Jump as Investors Bet on US Policy Shift

China's Cleantech Stocks Jump as Investors Bet on US Policy Shift

FAQ